Literature DB >> 20963319

A single center 14 years study of infectious complications leading to hospitalization of patients with primary antibody deficiencies.

Setareh Mamishi1, Aiden Nasiri Eghbali, Nima Rezaei, Hassan Abolhassani, Nima Parvaneh, Asghar Aghamohammadi.   

Abstract

Primary antibody deficiencies (PADs) are a heterogeneous group of disorders, characterized by hypogammaglobulinemia and increased susceptibility to bacterial infections, leading to hospitalizations. This study was performed to determine the main infectious causes of hospital admissions in selective Iranian patients with PADs. Forty patients with PADs, who were admitted to the Infectious Ward of Children's Medical Center Hospital during a 14-year period, were reviewed in this study. There were 115 documented episodes of hospital admission during a 14-year period. The average length of hospital stay was 33.30 ± 25.72 days. Pneumonia was the most prominent infection leading to hospitalization among these patients (n = 48), followed by gastroenteritis (n = 23). Other less frequent causes of hospitalization were fever and neutropenia, septic arthritis, encephalitis, orbital cellulitis, sepsis, urinary tract infection, meningitis, oral ulcer, and lung abscess. The most common causative organisms of diarrhea were: Giardia lamblia, followed by Candida albicans, and Salmonella sp. Many patients with PADs suffer from repeated infections leading to hospitalization, in spite of immunoglobulin replacement therapy. Respiratory tract infections were the prominent cause of hospitalization among studied patients, followed by gastrointestinal infections.

Entities:  

Mesh:

Year:  2010        PMID: 20963319

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   1.949


  5 in total

1.  Primary immunodeficiency disorders in Iran: update and new insights from the third report of the national registry.

Authors:  Asghar Aghamohammadi; Payam Mohammadinejad; Hassan Abolhassani; Babak Mirminachi; Masoud Movahedi; Mohammad Gharagozlou; Nima Parvaneh; Vaheid Zeiaee; Bahram Mirsaeed-Ghazi; Zahra Chavoushzadeh; Alireza Mahdaviani; Mahboubeh Mansouri; Sedigheh Yousefzadegan; Bahareh Sharifi; Fariborz Zandieh; Ehsan Hedayat; Ali Nadjafi; Roya Sherkat; Behzad Shakerian; Mahnaz Sadeghi-Shabestari; Reza Farid Hosseini; Farahzad Jabbari-Azad; Hamid Ahanchian; Fatemeh Behmanesh; Mohammadreza Zandkarimi; Afshin Shirkani; Taher Cheraghi; Abbas Fayezi; Iraj Mohammadzadeh; Reza Amin; Soheila Aleyasin; Mojgan Moghtaderi; Javad Ghaffari; Saba Arshi; Naser Javahertrash; Mohammad Nabavi; Mohammad Hassan Bemanian; Alireza Shafiei; Najmedin Kalantari; Akefeh Ahmadiafshar; Hossein Ali Khazaei; Lida Atarod; Nima Rezaei
Journal:  J Clin Immunol       Date:  2014-05       Impact factor: 8.317

Review 2.  Infectious Complications Reporting in Common Variable Immunodeficiency: A Systematic Review and Meta-analysis.

Authors:  Hamed Zainaldain; Fatema Sadaat Rizvi; Hosein Rafiemanesh; Mahla Alizadeh; Mahnaz Jamee; Sara Mohammadi; Fatemeh Kiaee; Hamed Mohammadi; Farhad Babaie; Reza Yazdani; Hassan Abolhassani; Asghar Aghamohammadi; Gholamreza Azizi
Journal:  Oman Med J       Date:  2020-07-30

3.  Impaired release of antimicrobial peptides into nasal fluid of hyper-IgE and CVID patients.

Authors:  Andreas Cederlund; Marie Olliver; Rokeya Sultana Rekha; Monica Lindh; Lennart Lindbom; Staffan Normark; Birgitta Henriques-Normark; Jan Andersson; Birgitta Agerberth; Peter Bergman
Journal:  PLoS One       Date:  2011-12-27       Impact factor: 3.240

4.  Clinical and Laboratory Findings in Patients With Acute Respiratory Symptoms That Suggest the Necessity of Chest X-ray for Community-Acquired Pneumonia.

Authors:  Azadeh Ebrahimzadeh; Mahyar Mohammadifard; Godratallah Naseh; Alireza Mirgholami
Journal:  Iran J Radiol       Date:  2015-01-01       Impact factor: 0.212

5.  Mucosal IgA Prevents Commensal Candida albicans Dysbiosis in the Oral Cavity.

Authors:  Nicolas Millet; Norma V Solis; Marc Swidergall
Journal:  Front Immunol       Date:  2020-10-22       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.